Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 180

1.

Preclinical evaluation of sunitinib as single agent or in combination with chemotherapy in nasopharyngeal carcinoma.

Hui EP, Lui VW, Wong CS, Ma BB, Lau CP, Cheung CS, Ho K, Cheng SH, Ng MH, Chan AT.

Invest New Drugs. 2011 Dec;29(6):1123-31. doi: 10.1007/s10637-010-9451-1. Epub 2010 May 15.

PMID:
20467883
[PubMed - indexed for MEDLINE]
2.

Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.

Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.

Clin Cancer Res. 2009 May 15;15(10):3384-95. doi: 10.1158/1078-0432.CCR-08-2170. Epub 2009 May 5.

PMID:
19417025
[PubMed - indexed for MEDLINE]
Free Article
3.

Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.

Wang D, Jiang Z, Zhang L.

Med Oncol. 2012 Jun;29(2):600-6. doi: 10.1007/s12032-011-9905-0. Epub 2011 Apr 1.

PMID:
21455800
[PubMed - indexed for MEDLINE]
4.

Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.

Pan F, Tian J, Zhang X, Zhang Y, Pan Y.

J Cancer Res Clin Oncol. 2011 Sep;137(9):1397-408. doi: 10.1007/s00432-011-1009-x. Epub 2011 Jul 28.

PMID:
21796416
[PubMed - indexed for MEDLINE]
5.

Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.

Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P, Meyn R.

Radiat Oncol. 2012 Sep 11;7:154. doi: 10.1186/1748-717X-7-154.

PMID:
22967802
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.

Xiao X, Wu J, Zhu X, Zhao P, Zhou J, Liu QQ, Zheng L, Zeng M, Liu R, Huang W.

Int J Cancer. 2007 Nov 1;121(9):2095-104.

PMID:
17631646
[PubMed - indexed for MEDLINE]
7.

Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.

Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ.

PLoS One. 2012;7(10):e44372. doi: 10.1371/journal.pone.0044372. Epub 2012 Oct 2.

PMID:
23056179
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

Sonpavde G, Jian W, Liu H, Wu MF, Shen SS, Lerner SP.

Urol Oncol. 2009 Jul-Aug;27(4):391-9. doi: 10.1016/j.urolonc.2008.03.017. Epub 2008 Jun 4.

PMID:
18534874
[PubMed - indexed for MEDLINE]
9.

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity.

Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D.

Mol Cancer Ther. 2006 Jul;5(7):1774-82.

PMID:
16891463
[PubMed - indexed for MEDLINE]
Free Article
10.

Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.

Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, Iacobelli S.

Cancer Lett. 2008 Nov 8;270(2):229-33. doi: 10.1016/j.canlet.2008.05.007. Epub 2008 Jun 30.

PMID:
18586384
[PubMed - indexed for MEDLINE]
11.

Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.

Bagi CM, Gebhard DF, Andresen CJ.

Eur J Gastroenterol Hepatol. 2012 May;24(5):563-74. doi: 10.1097/MEG.0b013e328350916f.

PMID:
22314934
[PubMed - indexed for MEDLINE]
12.

Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.

Takeuchi A, Eto M, Shiota M, Tatsugami K, Yokomizo A, Kuroiwa K, Itsumi M, Naito S.

Int J Oncol. 2012 May;40(5):1691-6. doi: 10.3892/ijo.2012.1368. Epub 2012 Feb 13.

PMID:
22344606
[PubMed - indexed for MEDLINE]
13.

ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.

Gu WG, Huang Y, Yuan ZY, Peng RJ, Luo HT, He ZR, Wang SS.

Asian Pac J Cancer Prev. 2013;14(3):1787-90.

PMID:
23679274
[PubMed - indexed for MEDLINE]
Free Article
14.

Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor.

Wang D, Tang F, Wang S, Jiang Z, Zhang L.

Cancer Chemother Pharmacol. 2012 Jan;69(1):173-83. doi: 10.1007/s00280-011-1681-1. Epub 2011 Jun 3.

PMID:
21638122
[PubMed - indexed for MEDLINE]
15.

Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.

Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC.

Curr Cancer Drug Targets. 2009 Sep;9(6):738-47.

PMID:
19754358
[PubMed - indexed for MEDLINE]
16.

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM.

Mol Cancer Ther. 2003 May;2(5):471-8.

PMID:
12748309
[PubMed - indexed for MEDLINE]
Free Article
17.

Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.

Lopergolo A, Nicolini V, Favini E, Dal Bo L, Tortoreto M, Cominetti D, Folini M, Perego P, Castiglioni V, Scanziani E, Borrello MG, Zaffaroni N, Cassinelli G, Lanzi C.

J Clin Endocrinol Metab. 2014 Feb;99(2):498-509. doi: 10.1210/jc.2013-2574. Epub 2013 Nov 25.

PMID:
24276455
[PubMed - indexed for MEDLINE]
18.

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.

Ma BB, Lui VW, Hui EP, Lau CP, Ho K, Ng MH, Cheng SH, Tsao SW, Chan AT.

Invest New Drugs. 2010 Aug;28(4):413-20. doi: 10.1007/s10637-009-9269-x. Epub 2009 May 27.

PMID:
19471857
[PubMed - indexed for MEDLINE]
19.

Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma.

Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT.

Cancer Res. 2010 Feb 1;70(3):1053-62. doi: 10.1158/0008-5472.CAN-09-3722. Epub 2010 Jan 26.

PMID:
20103629
[PubMed - indexed for MEDLINE]
Free Article
20.

Combination of pigment epithelium-derived factor with radiotherapy enhances the antitumor effects on nasopharyngeal carcinoma by downregulating vascular endothelial growth factor expression and angiogenesis.

Xu Z, Fang S, Zuo Y, Zhang Y, Cheng R, Wang Q, Yang Z, Cai W, Ma J, Yang X, Gao G.

Cancer Sci. 2011 Oct;102(10):1789-98. doi: 10.1111/j.1349-7006.2011.02013.x. Epub 2011 Jul 29.

PMID:
21707863
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk